Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
Published in
Journal of Experimental & Clinical Cancer Research, June 2013
Antonio Bianchi, Ferdinando Valentini, Raffaella Iuorio, Maurizio Poggi, Roberto Baldelli, Marina Passeri, Antonella Giampietro, Linda Tartaglione, Sabrina Chiloiro, Marialuisa Appetecchia, Patrizia Gargiulo, Andrea Fabbri, Vincenzo Toscano, Alfredo Pontecorvi, Laura De Marinis
Abstract
Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).
Pharmacology, Toxicology and Pharmaceutical Science
2
5%
Other
1
2%
Unknown
12
27%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2013.
All research outputs
#17,286,379
of 25,374,917 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#1,247
of 2,379 outputs
Outputs of similar age
#132,811
of 209,406 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#6
of 8 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,379 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,406 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.
